Trials / Completed
CompletedNCT00282048
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
Phase 2 Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the activity and response rate of AG-013736 in patients with advanced and refractory renal cell cancer, (patients who also failed on sorafenib-based therapy).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AG-013736 (axitinib) | AG-013736 5 mg twice daily \[bid\] continuous dosing in 28 day cycles. |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2009-02-01
- Completion
- 2009-06-01
- First posted
- 2006-01-25
- Last updated
- 2012-07-31
- Results posted
- 2012-04-03
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00282048. Inclusion in this directory is not an endorsement.